Experts are raising questions about FDA’s decision to expand the label of the diabetes drug Invokana to reduce the risk of cardiovascular events.
Questions Raised About Invokana Label Expansion For CV Risk Reduction
Experts are raising questions about FDA’s decision to expand the label of the diabetes drug Invokana to reduce the risk of cardiovascular events.